Sydnexis, Inc.

Inotek Pharmaceuticals Corporation

Chiron Ophthalmics, Inc.

Newport Research, Inc.

Wellspring Ophthalmics, Inc.

Riolan Technologies, Inc.

Harun Takruri

Kenneth J Widder

David S Baker

Gregory I Ostrow

William K McVicar

Mitchell H Friedlaender

Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.

Ophthalmic composition

Compositions that are aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporin A), a pharmaceutically acceptable water soluble solvent for the cyclosporin, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed.

Aqueous suspensions of cyclosporin

The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof.

Ophthalmic formulations

The present invention is related to a method for treating epiphora, the method comprising administering to a nasal area of a subject in need thereof a composition comprising camphor, eucalyptus oil, and menthol, wherein the composition is substantially free of lipids other than the eucalyptus oil.

Methods of treating epiphora

A method for inhibiting the oxidation of a polypeptide in a liquid or semi-solid pharmaceutical or therapeutic preparation, the polypeptides having an amino acid sequence comprising at least one methionine residue, wherein the amino acid methionine is added in a sufficient amount to inhibit the oxidation of the methionine residue(s) to methionine sulfoxide.

Growing community of inventors

Newport Beach, CA, United States of America

Harun Takruri